-
-
-
-
-
-
-
The Next Generation of the GLP-1 Revolution Is Already Underway
-
-
-
-
-
-
-
PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
-
-
-
-
-
-
-
Pfizer weight-loss drug data raises questions about side effects, shares fall
-
-
-
-
-
-
-
Quanterix names Everett Cunningham as new president and CEO
-
-
-
-
-
-
-
Pfizer provides 2026 financial guidance with lower revenue and earnings outlook
-
-
-
-
-
-
-
Pfizer amends merger deal with Metsera, raising value to $86.25 per share
-
-
-
-
-
-
-
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
-
1,157,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

